Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | FNTA | P49354 | 5/20 | 0.58 |
| ▸ | FNTB | P49356 | 4/20 | 0.58 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442285 | 1.00 | ALDH1A1 (0.67) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL6442287 | 1.00 | ALDH1A1 (0.67) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL6442863 | 0.98 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL6442870 | 0.98 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL31184576 | 0.98 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL9241222 | 0.88 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL12713313 | 0.88 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL14815392 | 0.88 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL3864697 | 0.88 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL397327 | 0.86 | ALDH1A1 (0.71) | ALDH1A1ALOX15FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | claimed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | claimed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | claimed |
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | disclosed |
| US-6432931-B1 | NITROGEN CONTAINING BISPHOSPHONATE COMPOUND | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | disclosed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | SOST, PTEN, ALPI | ALDH1A1 4552/4885ALOX15 441/4885FNTA 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.